Landec Corporation Cost of Revenue

Cost of Revenue of LNDC for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cost of Revenue growth rates and interactive chart. Cost of revenue refers to the direct costs attributable to the production of the goods or supply of services by an entity. It is also commonly known as the “cost of goods sold (COGS)”. Cost of sales measures the cost of goods produced or services provided in a period by an entity. It includes the cost of the direct materials used in producing the goods, direct labor costs used to produce the good, along with any other direct costs associated with the production of goods. In case of services cost of sales includes the labor cost or salaries of the employees and other directly attributable costs. Cost of sales does not include indirect expenses such as distribution costs and marketing costs. It appears on the income statement and is deducted from the sales revenue for the calculation of gross profit (or gross margin).


Highlights and Quick Summary

  • Cost of Revenue for the quarter ending February 27, 2021 was $118 Million (a 7.1% increase compared to previous quarter)
  • Year-over-year quarterly Cost of Revenue decreased by -10.56%
  • Annual Cost of Revenue for 2020 was $515 Million (a 8.15% increase from previous year)
  • Annual Cost of Revenue for 2019 was $477 Million (a 6.88% increase from previous year)
  • Annual Cost of Revenue for 2018 was $446 Million (a 14.17% increase from previous year)
  • Twelve month Cost of Revenue ending February 27, 2021 was $480 Million (a -2.99% decrease compared to previous quarter)
  • Twelve month trailing Cost of Revenue decreased by -6.92% year-over-year
Trailing Cost of Revenue for the last four month:
27 Feb '21 29 Nov '20 30 Aug '20 30 May '20
$480 Million $494 Million $511 Million $515 Million
Visit stockrow.com/LNDC for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cost of Revenue of Landec Corporation

Most recent Cost of Revenueof LNDC including historical data for past 10 years.

Interactive Chart of Cost of Revenue of Landec Corporation

Landec Corporation Cost of Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $118.09
2020 $110.27 $119.3 $132.04 $132.88 $515.38
2019 $127.08 $123.38 $126.57 $133.99 $476.56
2018 $107.67 $108.33 $116.27 $125.1 $445.89
2017 $107.54 $96.98 $49.27 $113.14 $390.56
2016 $116.91 $111.25 $52.52 $117.06 $470.14
2015 $123.18 $117.38 $115.78 $121.65 $473.85
2014 $117.0 $119.43 $104.79 $106.22 $414.25
2013 $106.29 $96.95 $94.08 $100.36 $378.95
2012 $96.2 $88.31 $67.91 $66.89 $265.41
2011 $68.56 $62.05 $57.55 $61.03 $230.03
2010 $58.31 $53.14 $48.86 $204.46

Business Profile of Landec Corporation

Sector: Consumer Defensive
Industry: Packaged Foods
Landec Corporation, together with its subsidiaries, designs, develops, manufactures, and sells differentiated health and wellness products for food and biomaterials markets. It operates through Curation Foods and Lifecore segments. The Curation Foods segment engages in processing, marketing, and selling of vegetable-based salads, and fresh-cut and whole vegetable products primarily under the Eat Smart brand, O branded olive oils and wine vinegars, and Yucatan and Cabo Fresh guacamole and avocado food products, as well as various private labels. It serves retail grocery chains, club stores, and food service operators. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology transfer, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. It sells its products directly to partners in the medical device and pharmaceutical markets. The company was founded in 1986 and is headquartered in Santa Clara, California.